HC Wainwright Has Optimistic Outlook of RNAZ FY2024 Earnings

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) – Equities research analysts at HC Wainwright increased their FY2024 EPS estimates for shares of TransCode Therapeutics in a report released on Wednesday, December 18th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($4.76) per share for the year, up from their previous estimate of ($60.73). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($60.73) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ Q4 2024 earnings at ($3.21) EPS, FY2025 earnings at ($4.37) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.77) EPS and FY2028 earnings at ($0.62) EPS.

TransCode Therapeutics Stock Down 2.3 %

Shares of TransCode Therapeutics stock opened at $3.76 on Monday. TransCode Therapeutics has a 52 week low of $3.21 and a 52 week high of $264.00. The business’s fifty day simple moving average is $380.38 and its 200-day simple moving average is $547.01.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TransCode Therapeutics stock. Sheets Smith Wealth Management boosted its stake in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 50,138 shares of the company’s stock after purchasing an additional 30,000 shares during the period. Sheets Smith Wealth Management owned about 0.29% of TransCode Therapeutics worth $29,000 at the end of the most recent quarter.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.